SCHEMBL7963490

SCHEMBL7963490

Fc1cc(Cl)ccc1C1CCN(CCCc2nnc3n2CCCCC3)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
SHMT2 P34897 1/20 0.46
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PKM P14618 1/20 0.44
HPGD P15428 2/20 0.42
POLB P06746 2/20 0.42
HTR1A P08908 2/20 0.40
HTR2A P28223 2/20 0.40
ADRA1D P25100 2/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADRA1A P35348 1/20 0.40
DRD3 P35462 1/20 0.40
HTR2B P41595 1/20 0.40
HTT P42858 1/20 0.39
OPRL1 P41146 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7964092 0.89 PKM (0.53) LMNASHMT2GAASMN1; SMN2PKM
SCHEMBL7959264 0.85 LMNA (0.53) LMNASHMT2GAASMN1; SMN2PKM
SCHEMBL7964136 0.84 GAA (0.52) LMNASHMT2GAASMN1; SMN2PKM
SCHEMBL7957361 0.84 DRD2 (0.48) LMNASHMT2GAASMN1; SMN2PKM
Hydrochloric Acid SCHEMBL8570980 0.83 DRD2 (0.47) GAASMN1; SMN2PKMHPGDPOLB
SCHEMBL7959555 0.83 LMNA (0.46) LMNASHMT2GAASMN1; SMN2PKM
SCHEMBL7959422 0.82 DRD2 (0.44) LMNASHMT2GAASMN1; SMN2HPGD
SCHEMBL7961353 0.82 HTR1A (0.47) LMNASHMT2GAASMN1; SMN2HPGD
SCHEMBL7959113 0.80 L3MBTL1 (0.41) LMNASHMT2GAASMN1; SMN2PKM
SCHEMBL7957315 0.80 LMNA (0.51) LMNAPOLBHTR1AHTR2AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6187774-B1 N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2001-02-13 US disclosed
EP-0885883-A1 FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-12-23 EP disclosed